Danggui Beimu Kushen Pill Alleviates Colitis-Induced Inflammation in Mice by Regulating the IL-6/IL-6R and IL-17A/IL-17RA Signaling Pathways DOI Creative Commons

Shuo Gong,

Ran Xu, Yuqing Wang

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 141 - 141

Published: Jan. 22, 2025

Background/Objectives: Danggui Beimu Kushen pill (DBK) is a traditional Chinese medicine renowned for its efficacy in the treatment of inflammatory conditions. It has been used modern clinical ulcerative colitis (UC). Further research required to clarify underlying mechanisms. Methods: DBK compounds were analyzed using UPLC-ESI-MS/MS. A mouse model Dextran sulfate sodium (DSS)-induced UC was assess DBK. Network pharmacology identified targets UC, which validated by molecular docking simulations. Cytokine levels quantified ELISA. Western blotting, immunofluorescence (IF), and immunohistochemistry (IHC) employed explore Results: enhanced body weight colon length mice with DSS-induced colitis. Inflammatory cytokine (TNF-α, IL-1β, IL-6, IL-23, IL-17A) notably decreased both serum tissues. analyses IL-6/IL-6R IL-17A/IL-17RA signaling pathways as crucial UC. Additional validation WB, IHC, IF demonstrated that alleviated suppressing IL-6/STAT3 IL-17/TRAF6/NF-κB pathways. Conclusions: mitigates intestinal injury exerts therapeutic effects on inhibiting reduce inflammation. These findings provide significant insights into mechanism

Language: Английский

Danggui Beimu Kushen Pill Alleviates Colitis-Induced Inflammation in Mice by Regulating the IL-6/IL-6R and IL-17A/IL-17RA Signaling Pathways DOI Creative Commons

Shuo Gong,

Ran Xu, Yuqing Wang

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 141 - 141

Published: Jan. 22, 2025

Background/Objectives: Danggui Beimu Kushen pill (DBK) is a traditional Chinese medicine renowned for its efficacy in the treatment of inflammatory conditions. It has been used modern clinical ulcerative colitis (UC). Further research required to clarify underlying mechanisms. Methods: DBK compounds were analyzed using UPLC-ESI-MS/MS. A mouse model Dextran sulfate sodium (DSS)-induced UC was assess DBK. Network pharmacology identified targets UC, which validated by molecular docking simulations. Cytokine levels quantified ELISA. Western blotting, immunofluorescence (IF), and immunohistochemistry (IHC) employed explore Results: enhanced body weight colon length mice with DSS-induced colitis. Inflammatory cytokine (TNF-α, IL-1β, IL-6, IL-23, IL-17A) notably decreased both serum tissues. analyses IL-6/IL-6R IL-17A/IL-17RA signaling pathways as crucial UC. Additional validation WB, IHC, IF demonstrated that alleviated suppressing IL-6/STAT3 IL-17/TRAF6/NF-κB pathways. Conclusions: mitigates intestinal injury exerts therapeutic effects on inhibiting reduce inflammation. These findings provide significant insights into mechanism

Language: Английский

Citations

0